Peptide Based Metabolic Disorders Therapeutics Global Market Report 2024

Description

Peptide-based therapeutics for metabolic disorders are pharmaceutical treatments derived from short chains of amino acids, known as peptides. These therapies target and modulate biological pathways involved in conditions such as diabetes, obesity, and related disorders. Their primary objectives include regulating hormone levels, improving insulin sensitivity, managing appetite, and controlling glucose metabolism, all aimed at enhancing patient outcomes and quality of life.

Key drugs in the peptide-based treatment of metabolic disorders include liraglutide, exenatide, and others. Liraglutide belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which mimic the action of natural GLP-1. This hormone regulates blood sugar levels by stimulating insulin release and inhibiting glucagon secretion. Liraglutide is utilized in the treatment of conditions such as lysosomal storage diseases, diabetes, obesity, hypercholesterolemia, among others. Distribution channels for these therapies include hospital pharmacies, retail pharmacies, and online pharmacies.

The peptide based metabolic disorders therapeutics market research report is one of a series of new reports from the business research company that provides peptide based metabolic disorders therapeutics market statistics, including peptide based metabolic disorders therapeutics industry global market size, regional shares, competitors with an peptide based metabolic disorders therapeutics market share, detailed peptide based metabolic disorders therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide based metabolic disorders therapeutics industry. This peptide based metabolic disorders therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide based metabolic disorders therapeutics market size has grown rapidly in recent years. It will grow from $26.03 billion in 2023 to $29.89 billion in 2024 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to increasing prevalence of metabolic disorders, advancements in peptide synthesis technologies, rising healthcare expenditures, a growing aging population, expansion of the biopharmaceutical sector, regulatory approvals for new therapies, and heightened awareness about personalized medicine.

The peptide based metabolic disorders therapeutics market size is expected to see rapid growth in the next few years. It will grow to $52.16 billion in 2028 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to several key factors, including the development of novel peptide analogs, increased research and development investments in metabolic disorders, adoption of precision medicine approaches, expansion in emerging markets, collaborations and partnerships in drug development, advancements in delivery technologies, and a focus on patient-centric therapies. Key trends anticipated in the forecast period include the application of artificial intelligence in drug discovery, the growth of personalized therapies, utilization of CRISPR/Cas9 for genetic therapies, integration of wearable devices for patient monitoring, development of oral peptide formulations, the emergence of digital therapeutics in disease management, and expansion of biobanking for personalized treatments. These trends are expected to significantly shape and propel the peptide-based metabolic disorders therapeutics market in the years to come.

The increasing prevalence of obesity is expected to drive growth in the peptide-based metabolic disorders therapeutic market in the foreseeable future. Obesity, characterized by excessive accumulation of body fat and associated health risks, is becoming more prevalent due to factors such as sedentary lifestyles, unhealthy diets, genetic predisposition, and environmental influences promoting calorie-dense foods and physical inactivity. Peptide-based therapies for metabolic disorders aim to manage conditions such as obesity by utilizing peptides to regulate metabolic functions, improve insulin sensitivity, and control appetite, thereby enhancing patient outcomes and reducing long-term health complications associated with these chronic disorders. For example, a report from the UK's Office for Health Improvement and Disparities noted in May 2023 that 63.8% of adults in England aged 18 and older were estimated to be overweight or obese in the period from 2021 to 2022, up slightly from 63.3% the previous year. Hence, the increasing prevalence of obesity is a key driver for the peptide-based metabolic disorders therapeutic market.

Leading companies in the peptide-based metabolic disorders therapeutic market are focusing on developing innovative treatments, such as biosimilar versions of peptide-based anti-diabetic drugs, to address unmet medical needs and broaden treatment options for patients. Peptide-based anti-diabetic biosimilars replicate existing peptide therapies for diabetes, offering similar efficacy and safety profiles at potentially lower costs through competitive pricing strategies. For instance, Glenmark Pharmaceuticals Ltd., based in India, launched Lirafit in January 2024, a biosimilar of Liraglutide, a popular anti-diabetic medication belonging to the GLP-1 receptor agonist class. These drugs mimic the action of the natural GLP-1 hormone, crucial for regulating blood sugar levels. Clinical trials have demonstrated Lirafit's effectiveness in improving glycemic control, promoting weight loss, and enhancing cardiovascular safety, which are critical benefits in managing diabetes, obesity, and related cardiovascular conditions.

In December 2023, Roche Holding AG, a healthcare company based in Switzerland, completed the acquisition of Carmot Therapeutics Inc. for $2.7 billion. Through this transaction, Roche secures access to Carmot's clinical-stage incretins, including CT-388, a dual GLP-1/GIP receptor agonist currently in Phase 2 trials. This compound holds promise for treating obesity in both diabetic and non-diabetic patients. Carmot Therapeutics Inc., a clinical-stage biotechnology firm, focuses on developing peptide-based therapeutics primarily aimed at metabolic disorders such as diabetes and obesity.

Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group

North America was the largest region in the peptide based metabolic disorders therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peptide based metabolic disorders therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide-based metabolic disorders therapeutics market consists of sales of semaglutide, dulaglutide, albiglutide, and pramlintide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide Based Metabolic Disorders Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide based metabolic disorders therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide based metabolic disorders therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peptide based metabolic disorders therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Type: Liraglutide; Exenatide; Other Drug Type
2) By Application: Lysosomal Storage Diseases; Diabetes; Obesity; Hypercholesterolemia; Other Applications
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Roche Holding AG; Merck And Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r19203

1. Executive Summary

2. Peptide Based Metabolic Disorders Therapeutics Market Characteristics

3. Peptide Based Metabolic Disorders Therapeutics Market Trends And Strategies

4. Peptide Based Metabolic Disorders Therapeutics Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Peptide Based Metabolic Disorders Therapeutics Market Size and Growth

5.1. Global Peptide Based Metabolic Disorders Therapeutics Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Peptide Based Metabolic Disorders Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Peptide Based Metabolic Disorders Therapeutics Market Segmentation

6.1. Global Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Liraglutide
Exenatide
Other Drug Type
6.2. Global Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Lysosomal Storage Diseases
Diabetes
Obesity
Hypercholesterolemia
Other Applications
6.3. Global Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

7. Peptide Based Metabolic Disorders Therapeutics Market Regional And Country Analysis

7.1. Global Peptide Based Metabolic Disorders Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Peptide Based Metabolic Disorders Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market

8.1. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Peptide Based Metabolic Disorders Therapeutics Market

9.1. China Peptide Based Metabolic Disorders Therapeutics Market Overview
9.2. China Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Peptide Based Metabolic Disorders Therapeutics Market

10.1. India Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Peptide Based Metabolic Disorders Therapeutics Market

11.1. Japan Peptide Based Metabolic Disorders Therapeutics Market Overview
11.2. Japan Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Peptide Based Metabolic Disorders Therapeutics Market

12.1. Australia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Peptide Based Metabolic Disorders Therapeutics Market

13.1. Indonesia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Peptide Based Metabolic Disorders Therapeutics Market

14.1. South Korea Peptide Based Metabolic Disorders Therapeutics Market Overview
14.2. South Korea Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Peptide Based Metabolic Disorders Therapeutics Market

15.1. Western Europe Peptide Based Metabolic Disorders Therapeutics Market Overview
15.2. Western Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Peptide Based Metabolic Disorders Therapeutics Market

16.1. UK Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Peptide Based Metabolic Disorders Therapeutics Market

17.1. Germany Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Peptide Based Metabolic Disorders Therapeutics Market

18.1. France Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Peptide Based Metabolic Disorders Therapeutics Market

19.1. Italy Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Peptide Based Metabolic Disorders Therapeutics Market

20.1. Spain Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market

21.1. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market Overview
21.2. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Peptide Based Metabolic Disorders Therapeutics Market

22.1. Russia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Peptide Based Metabolic Disorders Therapeutics Market

23.1. North America Peptide Based Metabolic Disorders Therapeutics Market Overview
23.2. North America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Peptide Based Metabolic Disorders Therapeutics Market

24.1. USA Peptide Based Metabolic Disorders Therapeutics Market Overview
24.2. USA Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Peptide Based Metabolic Disorders Therapeutics Market

25.1. Canada Peptide Based Metabolic Disorders Therapeutics Market Overview
25.2. Canada Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Peptide Based Metabolic Disorders Therapeutics Market

26.1. South America Peptide Based Metabolic Disorders Therapeutics Market Overview
26.2. South America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Peptide Based Metabolic Disorders Therapeutics Market

27.1. Brazil Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Peptide Based Metabolic Disorders Therapeutics Market

28.1. Middle East Peptide Based Metabolic Disorders Therapeutics Market Overview
28.2. Middle East Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Peptide Based Metabolic Disorders Therapeutics Market

29.1. Africa Peptide Based Metabolic Disorders Therapeutics Market Overview
29.2. Africa Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Peptide Based Metabolic Disorders Therapeutics Market Competitive Landscape And Company Profiles

30.1. Peptide Based Metabolic Disorders Therapeutics Market Competitive Landscape
30.2. Peptide Based Metabolic Disorders Therapeutics Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson And Johnson
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Roche Holding AG
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Merck And Co. Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. AbbVie Inc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Peptide Based Metabolic Disorders Therapeutics Market Other Major And Innovative Companies

31.1. Sanofi SA
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca PLC
31.4. Novartis AG
31.5. Takeda Pharmaceutical Company Limited
31.6. GlaxoSmithKline plc
31.7. Boehringer Ingelheim International GmbH
31.8. Eli Lilly Company
31.9. Amgen Inc.
31.10. Gilead Sciences Inc.
31.11. Novo Nordisk A/S
31.12. Teva Pharmaceutical Industries Ltd.
31.13. Regeneron Pharmaceuticals Inc.
31.14. Biogen Inc.
31.15. Vertex Pharmaceuticals Incorporated

32. Global Peptide Based Metabolic Disorders Therapeutics Market Competitive Benchmarking

33. Global Peptide Based Metabolic Disorders Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Peptide Based Metabolic Disorders Therapeutics Market

35. Peptide Based Metabolic Disorders Therapeutics Market Future Outlook and Potential Analysis

35.1 Peptide Based Metabolic Disorders Therapeutics Market In 2028 - Countries Offering Most New Opportunities
35.2 Peptide Based Metabolic Disorders Therapeutics Market In 2028 - Segments Offering Most New Opportunities
35.3 Peptide Based Metabolic Disorders Therapeutics Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer